Investors & Media

Investors & Media

Corporate Profile

Aileron Therapeutics is a clinical stage company discovering and developing novel medicines for the treatment of cancer and cancer-supportive care by targeting high-value and historically undruggable intracellular targets using a proprietary platform of stabilized cell-permeating peptides. Our lead product candidate, ALRN-6924, is a first-in-class dual MDM2/MDMX inhibitor that has been tested in hematologic cancer and is currently being evaluated in a Phase 2 clinical trial in combination with Pfizer’s palbociclib (Ibrance®) for the treatment of MDM2-amplified advanced solid tumors, and in a Phase 1b/2 clinical trial to evaluate ALRN-6924 as a myelopreservative agent to protect against chemotherapy-induced toxicities. 

More >>


Copyright West LLC. Minimum 15 minutes delayed.

Recent News

Phase 1b/2 clinical trial of ALRN-6924 as a myelopreservation agent for the protection against chemotherapy-induced toxicity in small cell lung cancer started dosing patients September 2019 ; interim ...
WATERTOWN, Mass. , Dec. 18, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides, announced today the promotion ...
Announced positive interim results from its ongoing Phase 2a clinical trial evaluating the combination of ALRN-6924 and Pfizer’s IBRANCE® (palbociclib) for the treatment of patients with tumors harbor...

Upcoming Events

More events are coming soon.

Investor Contacts

Rick Wanstall

Vice President, Finance and Operations

LifeSci Advisors, LLC.

Hans C. Vitzthum